Research programme: trypanosomiasis therapies - DNDi/Pace University/SCYNEXIS/University of Dundee

Drug Profile

Research programme: trypanosomiasis therapies - DNDi/Pace University/SCYNEXIS/University of Dundee

Latest Information Update: 19 Jul 2014

Price : $50

At a glance

  • Originator Drugs for Neglected Diseases Initiative Foundation; Pace University; SCYNEXIS; University of Dundee
  • Class Piperidines; Small molecules; Thiazoles
  • Mechanism of Action Glycogen synthase kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Trypanosomiasis

Most Recent Events

  • 17 Jul 2014 No development reported - Preclinical for Trypanosomiasis in United Kingdom (PO)
  • 17 Jul 2014 No development reported - Preclinical for Trypanosomiasis in USA (PO)
  • 20 Aug 2009 Preclinical trials in Trypanosomiasis in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top